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The paper from McNally et al in this issue is interesting in that it
raises many issues well beyond what the authors probably
conceived when they started out on the project. Guidelines are
written for a number of reasons: firstly, to help health-care
providers plan their treatments and the delivery of the service.
Secondly, it is increasingly recognised that patients should be
treated using standardised protocols or schedules that allow
consistency of approach and they are important when involving
clinical governance. There may be financial or budgetary
advantages to standardised treatments and finally audit is
facilitated. The paper ostensibly looks at the application of
guidelines into clinical practice and populations. These include
the applicability of transferring clinical research and trials into
practice, the issues of applicability to whole populations especially
when this may involve rurality on the one hand and high levels of
social deprivation on the other hand. When looking at whole
populations, one realises that a population-based survey should
encompass the whole gamut of clinical indications and clinical
situations. Furthermore, there will be huge differences nationally
and internationally between the composition of the population as
determined by their social deprivation status, accessibility to
transport and other compounding factors.
The translation of clinical research into clinical practice is rarely
a straightforward issue. Patients entering into clinical trials are
required to fit into selection criteria that are generally far more
strict than those that are used to select patients for routine
treatments. These criteria usually require patients to be of good
performance status and to have normal or near-normal biochem-
istry and haematology, which fit the parameters consistent with
drug toxicity, and for there to be any lack of significant ill health or
other contraindicating factor to permit clinical trial entry.
However, there are also other issues that are commonly not
considered when patients are selected for clinical trial entry, which
may not be apparent to all clinicians. Scotland is an interesting and
diverse country for clinical trial recruitment and one would think
that with a population of 5000000 and only five designated cancer
centres, it would be possible to incorporate the majority of suitable
or eligible patients into clinical trials or to offer the optimal and
best designed treatments. The paper by McNally et al illustrates
some of the problems when a community is examined for the
ability of its patients to receive optimal recommended treatments.
Issues such as rurality and the distance between the patient’s home
and the cancer centre can often be limiting factors in choosing the
patient’s appropriateness and suitability for treatment. The
Grampian region in the North East of Scotland covers a large
geographical area with a majority of population located in the
urban area of Aberdeen, but provides a cancer referral practice for
patients living up to 100 miles (160km) away on the mainland and
also provides cover for patients living on the Shetland Islands
which are some 10–12h by ferry or an hour by aeroplane. This is
in complete contrast to an urban population such as Glasgow
where 3000000 people live within 35 miles (55km) from the city
centre that houses some of the worse social deprivation in Europe.
Thus, patients can live within five miles of the second largest
cancer centre in the UK and yet not be suitable candidates for
optimal treatment.
So, what is optimal treatment, how do we define it and who
defines it? NICE in England and Wales (with Scottish equivalents
in CSBS (Clinical Standards Board Scotland), HTBS (Health
Technology Board Scotland) and its successor NHSQIS National
Health Service Quality Improvement Scotland, and the Scottish
Medicines Consortium) have tried to make recommendations for
treatment. Prior to the publication of the results of the ICON-3
paper on ovarian cancer, it looked as though the combination of a
platinum and a taxane such as carboplatin and taxol was the
optimal treatment for first-line chemotherapy in advanced ovarian
cancer. This certainly would be the viewpoint held in both the
United States and much of mainland Europe. However, the
apparent equivalence of carboplatin (or CAP) to carboplatin and
taxol in the ICON-3 study has thrown open to question–what is
the optimal treatment for ovarian cancer? Opinion is strongly
divided as to whether carboplatin given at optimal dosage is an
adequate treatment for these patients. This viewpoint would be
difficult to substantiate in the USA, but what this paper reviews is
what actually happens in clinical practice, that is, how many
patients are actually fit enough and well enough to receive the
combination? The paper examined patients in the Grampian
region over a 3-year period who were referred in for treatment of
ovarian cancer. Virtually, all the patients were treated surgically in
the regional cancer centre at Aberdeen. A proportion of patients
had stage 1 disease of low risk for whom adjuvant treatment was
not indicated, but there remained 117 out of 133 patients who were
identified as requiring chemotherapy. For a variety of reasons, a
number of other patients were deemed unsuitable for treatment so
that only 106 were left, and of these only 68 were deemed fit
enough for a Platinum/ Taxane combination either with paclitaxel/
carboplatin or docetaxel/carboplatin (some of these patients were *Correspondence: Dr N Reed; E-mail: nicksreed@aol.com
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evaluating the latter carboplatin and docetaxel combination).
It initially seems very disappointing that so few patients (not a
great deal more than 50%) actually received the platinum/taxane
combination, and yet there were very good reasons why many of
the patients were treated with carboplatin alone. Of the patients
receiving carboplatin only, 38 had a median age of 76 years. This
has important consequences for health service planners when
trying to determine budgets and services and also when trying to
determine the number of patients likely to enter into clinical trials.
Incidentally, one must compliment them on achieving 29%
participation in clinical trials, which is substantially above the
national averages. Our population is ageing and therefore we are
likely to see more patients who will be deemed unsuitable for
intensive treatment regimens. Currently, we are being encouraged
to improve clinical trial entry, but despite huge efforts to do this, a
large cohort of patients are not suitable for recruitment. With this
in mind, the Scottish Gynaecological Cancer Group has been
considering ideas for carboplatin-based protocols to evaluate fixed
dosing vs flexible dosing in the management of these trials. Recent
informal discussions about the applicability of this trial to clinical
practice have raised enormous variations in approach throughout
Europe with some specialists indicating that virtually all their
patients can be treated with platinum/taxane and yet here we have
substantial and significant evidence to question that approach.
It is often not appreciated by those who do not work with
patients from areas of high levels of social deprivation that there
are special problems. Ignorance, fear and lack of understanding
are only some of the issues. Lack of transport and support are
often equally problematic. It is in major contrast to areas where
the articulate, educated and affluent arrive in the clinic with
sheaves of pages downloaded from the Internet. There is a strange
paradox that the more socially deprived patients anticipate that
the doctor knows best and should be able to advise or recommend
the best treatment. The apparent uncertainty in the specialist
may undermine patient’s confidence and inhibit clinical trial
entry. While for those with excessive knowledge (and remember
a little learning can be a dangerous thing), too much knowledge
can bring its own problems in trying to encourage recruitment into
clinical trials.
We must commend the Aberdeen Group for entering nearly 30%
of their patients into clinical trials, which is well above the National
average. It also clearly supports the concept of a unified service
where all the patients are treated in a single centre. This concept
should be embraced by planners in defining future cancer trial
organisations. There is a movement towards decentralisation at
present, but the proof of the pudding will lie in the eating in that
the major centres are much more likely to enter a higher
proportion of patients into clinical trials, although they must have
the appropriate infrastructure to support this.
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